The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
"Too often, obstructive sleep apnea is brushed off as 'just snoring' - but it's far more than that," said Julie Flygare, CEO ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...
The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...
The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the ...
In one trial where participants did not use CPAP ... cost vial option, to help ease financial barriers. However, without insurance, monthly costs can still exceed $1,000. If you have sleep apnea ...